 |
|
Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy
Jennifer J. Griggs, MD, MPH;
Melony E. S. Sorbero, PhD, MS, MPH;
Gary H. Lyman, MD, MPH
Arch Intern Med. 2005;165:1267-1273.
Background Systematic undertreatment of breast cancer in overweight and obese women may contribute to the poorer prognosis in these women. The objective of this study was to investigate treatment patterns in overweight and obese women undergoing breast cancer adjuvant chemotherapy.
Methods We performed a retrospective cohort study of 9672 women treated with doxorubicin hydrochloride and cyclophosphamide between 1990 and 2001. The main outcome measure was the quality of chemotherapy as measured by the use of reduced doses for the first treatment (compared with standard doses), the overall dose proportion (actual-expected dose ratio), and relative dose intensity.
Results First-cycle dose reductions (defined as a dose proportion of <0.9 compared with standard published doses) were administered to 9% of the healthy weight, 11% of the overweight, 20% of the obese, and 37% of the severely obese women (P<.001). First-cycle reduction was independently associated with being overweight (P = .03), obese (P<.001), severely obese (P<.001), older than 60 years (P<.001), and having a serious comorbid condition (P = .03). Practices varied greatly in the use of dose reductions in overweight and obese patients. Severe obesity was independently associated with a lower likelihood of admission for febrile neutropenia, even among those subjects given full weight-based doses (odds ratio, 0.61; 95% confidence interval, 0.38-0.97).
Conclusions Overweight and obese women with breast cancer often receive intentionally reduced doses of adjuvant chemotherapy. Administration of initial and overall full weight-based doses of adjuvant chemotherapy in overweight and obese women is likely to improve outcomes in this group of patients.
Author Affiliations: Departments of Medicine (Hematology/Oncology) (Drs Griggs and Lyman) and Community & Preventive Medicine (Dr Griggs), University of Rochester, Rochester, NY; and RAND Corporation, Pittsburgh, Pa (Dr Sorbero).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Obesity and Cancer Treatment: Weighing the Evidence
Griggs and Sabel
JCO 2008;26:4060-4062.
FULL TEXT
Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey
Field et al.
J Oncol Pract 2008;4:108-113.
ABSTRACT
| FULL TEXT
Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern
Lyman
J Oncol Pract 2008;4:114-115.
FULL TEXT
Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study
Bertelsen et al.
JNCI J Natl Cancer Inst 2008;100:32-40.
ABSTRACT
| FULL TEXT
Obesity in Dose Calculation: A Mouse or an Elephant?
Gurney and Shaw
JCO 2007;25:4703-4704.
FULL TEXT
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
Sparreboom et al.
JCO 2007;25:4707-4713.
ABSTRACT
| FULL TEXT
Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter?
Armstrong et al.
JCO 2007;25:4477-4489.
ABSTRACT
| FULL TEXT
Receipt of Appropriate Primary Breast Cancer Therapy and Adjuvant Therapy Are Not Associated With Obesity in Older Women With Access to Health Care
Buist et al.
JCO 2007;25:3428-3436.
ABSTRACT
| FULL TEXT
Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?
Mathijssen et al.
The Oncologist 2007;12:913-923.
ABSTRACT
| FULL TEXT
Body Mass Index and Mortality among Older Breast Cancer Survivors in the Study of Osteoporotic Fractures
Reeves et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1468-1473.
ABSTRACT
| FULL TEXT
Relation of Body Mass Index (BMI) to Disease Free (DFS) and Distant Disease Free Survivals (DDFS) Among Turkish Women with Operable Breast Carcinoma
Demirkan et al.
Jpn J Clin Oncol 2007;37:256-265.
ABSTRACT
| FULL TEXT
Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy
Griggs et al.
JCO 2007;25:277-284.
ABSTRACT
| FULL TEXT
Developing a New Framework for Dose Calculation
Gurney
JCO 2006;24:1489-1490.
FULL TEXT
|
